News

In this week’s Pointers with Portela, the 208SkinDoc reviews a case of pediatric keratoderma.

This Hidradenitis Suppurativa Awareness Week, the Dermatology Times® team is spotlighting the often misunderstood condition and providing clinicians with the latest information in treatment and research.

Click here to answer this week's poll.

This week is Hidradenitis Suppurativa Awareness Week.

Level Ex, Inc.'s Top Derm is changing the way dermatologists learn about skin conditions—all through a cell phone screen.

Considering the whole patient is crucial in understanding how natural alternatives can improve the skin.

CEO Daniela Marino, PhD, emphasizes that the Switzlerand based company has received Orphan Drug Designation from the Swissmedic, EMA, and FDA, for its personalized human skin graft.

The chemical peel demonstrated tolerability and photoaging improvement.

This week is Hidradenitis Suppurativa Awareness Week.

More research is needed to specify long-term efficacy of the treatment and its ideal dose.

Weiss is the managing director of dermatology at OM1, a data analytics company with a health care focus.

This week is Hidradenitis Suppurativa Awareness Week.

The IL-23p19 inhibitor demonstrated long-term efficacy and safety.

Certain skin conditions such as atopic dermatitis and psoriasis are associated with sleep disturbances and disorders.

This week is Hidradenitis Suppurativa Awareness Week.

Researchers indicated no existing strategy for detecting skin wrinkles in vitro.

Restylane Eyelight is the first and only US product that uses NASHA Technology to improve the appearance of undereye hollows for up to 18 months.

This June, there are several awareness days and month designations supporting patients with dermatologic conditions.

Principal investigator Jason Luke, MD, discusses what the new data means for melanoma treatment moving forward.

ICYMI, this week we had stories about dermatologic disparities among veterans and LGBTQIA+ patients, pediatric melanoma, a European approval for hidradenitis suppurativa, and more.

Researchers examined the disease while going beyond current diagnostic tools.

The World Health Organization shared its enthusiasm for the “appropriate” use of these technologies. However, they are calling for caution to be exercised to protect and promote human well-being, safety, and autonomy and preserve public health.

Scientists have found a new therapy for the severe inflammatory skin disorder.

The approval makes the drug Europe’s first and only IL-17A inhibitor approved for the condition.

As Pride Month begins, the Dermatology Times® team wants to uplift LGBTQIA+ clinicians, patients, and topics in dermatology.

Apremilast is being examined for the treatment of psoriatic arthritis.

As senior director, Del Rosso is looking forward to presenting numerous sessions and welcoming attendees to Orlando.

A public exhibition spotlighting individuals with birthmarks improved participants’ wellbeing and sense of self image.

The phase 3b trial showed improvements to minimal disease activity in adults with the condition.

Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are popular for the month of May.